Lately, evidence thus far indicated that YTHDF1 deficiency inhibits the EMT process and AKT/GSK-3β/β-catenin signaling pathway in HCC (Bian et al., 2020). The gene discussed is AKT1; the disease is hepatocellular carcinoma.